8-K
Emergent BioSolutions Inc. (EBS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
____________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): July 29, 2011
Emergent BioSolutions Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-33137 | 14-1902018 |
|---|---|---|
| (State or Other Jurisdiction<br><br><br><br>of Incorporation) | (Commission<br><br><br><br>File Number) | (IRS Employer<br><br><br><br>Identification No.) |
| 2273 Research Boulevard, Suite 400, Rockville, Maryland | 20850 | |
| --- | --- | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (301) 795-1800
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01. Entry into a Material Definitive Agreement.
PNC Construction Loan Agreement
On July 29, 2011, Emergent BioSolutions Inc. (the “Registrant”), entered into a Loan Agreement (the “PNC Loan Agreement”) and related agreements with PNC Bank, National Association (“PNC”) under which PNC will provide a loan of up to $30.0 million to the Registrant based on periodic requests, primarily to fund the ongoing build-out of the Registrant’s Baltimore facility. A portion of the proceeds of the initial draw on the loan under the PNC Loan Agreement was used to make final payment on a pre-existing loan between Emergent Manufacturing Operations Baltimore LLC (“Emergent Manufacturing Operations”), a wholly-owned subsidiary of the Registrant, and HSBC Realty Credit Corporation (USA) (“HSBC”) related to the initial purchase of the Baltimore facility (the “HSBC Loan Agreement”). Additional information regarding the PNC Loan Agreement is set forth below in Item 2.03 and is incorporated by reference in this Item 1.01 in its entirety.
PNC Equipment Loan Agreement
On August 3, 2011, Emergent Manufacturing Operations and the Registrant entered into a separate loan agreement with PNC to provide a loan to fund equipment purchases at the Registrant’s Baltimore facility (the “Equipment Loan Agreement”). Under the Equipment Loan Agreement, PNC will make advances to the Registrant of up to $12.0 million through August 3, 2012 based on periodic requests from the Registrant. To date, the Registrant has not requested any advances under the Equipment Loan Agreement. Each request for advance under the Equipment Loan Agreement will be secured by the specific collateral described in such request, as well as by the Registrant’s other collateral securing the Registrant’s obligations under the PNC Loan Agreement. The Equipment Loan Agreement contains affirmative and negative covenants that are substantially similar to those contained in the PNC Loan Agreement, as well as covenants that are customary for equipment financings of this type. Negative covenants in the Equipment Loan Agreement limit the ability of the Registrant to incur indebtedness and liens; sell assets; make loans, advances or guarantees; and enter into certain mergers or similar transactions.
Item 2.02 Results of Operations and Financial Condition.
On August 4, 2011, the Company announced financial and operating results for the quarter ended June 30, 2011. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this Form 8-K, including Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The information set forth in Item 1.01 above with respect to the PNC Loan Agreement is incorporated by reference in this Item 2.03 in its entirety.
Under the PNC Loan Agreement, PNC will make advances to of up to $30.0 million through July 28, 2012 based on periodic requests from the Registrant. The Registrant has drawn $17.8 million on the loan to date, of which $6.2 million was used to repay the HSBC Loan Agreement. The Registrant is required to make monthly payments under the PNC Loan Agreement based on the amounts then outstanding, including interest based on certain options made available to the Registrant with respect to each draw on the loan. With respect to the initial draw on the loan, the Registrant’s interest rate is a one-month option of LIBOR plus 3.18725%. The Registrant’s payment obligations are secured by the accounts receivable of Emergent BioDefense Operations Lansing LLC that relate to BioThrax supply contracts with the U.S. government. Payment obligations relating to the PNC Loan Agreement may be accelerated upon the occurrence of an event of default under the PNC Loan Agreement or the Equipment Loan Agreement. Such events of default include, subject in some cases to specified cure periods, payment defaults; inaccuracy of representations and warranties in any material respect; defaults in the observance or performance of covenants; bankruptcy and insolvency related defaults; the entry of one or more final judgments for the payment of more than $500,000 million that are not satisfied within 30 days; uninsured loss or destruction of a material portion of the collateral; invalidity of loan documents relating to the PNC Loan Agreement; and the occurrence of a material adverse change in financial condition. The PNC Loan Agreement contains affirmative and negative covenants customary for financings of this type. Negative covenants in the PNC Loan Agreement limit the ability of the Registrant to incur indebtedness and liens; sell assets; make loans, advances or guarantees; and enter into certain mergers or similar transactions. The PNC Loan Agreement also contains financial covenants that require the Registrant and its consolidated subsidiaries to maintain a balance of unencumbered cash or liquid investments of $50,000,000; maintain on a quarterly basis, on a rolling four quarters basis, a ratio of all indebtedness for borrowed money to earnings before interest, taxes, depreciation and amortization for the most recent four quarters of less than 2.00 to 1.00; and maintain, on a quarterly basis, on a rolling four quarters basis, a ratio of earnings before interest, taxes, depreciation and amortization less cash taxes to the total current obligations and interest expense of indebtedness for borrowed money of at least 1.25 to 1.00.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Press Release dated August 4, 2011.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EMERGENT BIOSOLUTIONS INC.
By: /s/R. Don Elsey
R. Don Elsey
Chief Financial Officer
exhibit99.htm
EXHIBIT 99.1
FOR IMMEDIATE RELEASE
Investor Contact
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
Media Contact:
Tracey Schmitt
Vice President, Corporate Communications
301-795-1800
SchmittT@ebsi.com
EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER AND FIRST SIX MONTHS OF 2011
| · | 2Q and six month 2011 revenues of $88.1 and $106.7 million, respectively |
|---|---|
| · | 2Q net income of $14.2 million or $0.40 per share; six month net loss of |
| --- | --- |
| $7.2 million or $0.20 per share | |
| --- | |
| · | 2011 revised forecast: total revenues of $270 to $290 million and net income |
| --- | --- |
| of $15 to $25 million | |
| --- |
ROCKVILLE, MD, August 4, 2011—Emergent BioSolutions Inc. (NYSE: EBS) announced today its financial results for the second quarter and six months ended June 30, 2011.
Total revenues for the second quarter and first six months of 2011 were $88.1 million and $106.7 million, respectively. Net income for the second quarter was $14.2 million, or $0.40 per basic share, and for the first six months of 2011 the company recorded a net loss of $7.2 million, or $0.20 per basic share. The second quarter 2011 performance was primarily driven by sales of BioThrax® (Anthrax Vaccine Adsorbed) based on scheduled deliveries to the Strategic National Stockpile (SNS), revenues from US government development contracts and grants, and revenues from our collaborations with Abbott Laboratories (Abbott) and Pfizer Inc. (Pfizer).
R. Don Elsey, chief financial officer of Emergent BioSolutions, stated, “Our second quarter financial performance reflects the continued deliveries of BioThrax to the SNS under the modified current contract for 17.9 million doses and our ongoing commitment to control expenditures while investing in the development of our pipeline programs.”
2Q and First Six Months of 2011 Key Financial Results
Product Sales
For 2Q 2011, product sales were $71.5 million, an increase of $15.6 million, or 28 percent, from $55.9 million in 2Q 2010, primarily due to a 25% increase in the number of doses of BioThrax delivered. Product sales revenues for 2Q 2011 consisted of BioThrax sales to HHS of $70.7 million and aggregate international and other sales of $0.7 million.
For the six month period of 2011, product sales were $77.1 million, a decrease of $17.7 million, or 19 percent, from $94.7 million in the comparable period of 2010, primarily due to a 22% decrease in the number of doses of BioThrax delivered due to the company redeploying its potency testing capacity from BioThrax release testing to qualification of replacement reference standards and other development testing during the first quarter of 2011. Product sales revenues for the six months ended June 30, 2011 consisted of BioThrax sales to HHS of $75.8 million and aggregate international and other sales of $1.3 million.
Contracts and Grants Revenues
For 2Q 2011, contracts and grants revenue was $16.7 million, an increase of $10.4 million, or 166 percent, from $6.3 million in 2Q 2010. For the six month period of 2011, contracts and grants revenue was $29.6 million, an increase of $15.4 million, or 108 percent, from $14.2 million in the comparable period of 2010. The increase in contracts and grants revenue was primarily due to revenues from our contract from BARDA for large-scale manufacturing for BioThrax and our collaborations with Abbott and Pfizer, along with increased activity and associated revenue from our other development contracts with NIAID and BARDA.
Cost of Product Sales
For 2Q 2011, cost of product sales was $16.1 million, an increase of $5.0 million, or 45 percent, from $11.1 million in 2Q 2010. This increase was primarily attributable to the 25% increase in the number of BioThrax doses sold coupled with an increase in the cost per dose sold associated with decreased production yield in the period in which the doses were produced.
For the six month period of 2011, cost of product sales was $17.1 million, a decrease of $1.4 million, or 8 percent, from $18.6 million in the comparable period of 2010. This decrease was attributable to a 22% decrease in the number of doses of BioThrax delivered partially offset by an increase in the cost per dose sold associated with decreased production yield in the period in which the doses were produced.
Research and Development
For 2Q 2011, research and development expenses were $31.5 million, an increase of $12.9 million, or 69 percent, from $18.6 million in 2Q 2010. This increase primarily reflects higher contract service and personnel-related costs, and includes increased expenses of $12.4 million for product candidates and technology platform development activities that are categorized in the biosciences segment, increased expenses of $0.2 million for product candidates categorized in the biodefense segment, and increased expenses of $0.3 million in other research and development.
For the six month period of 2011, research and development expenses were $66.2 million, an increase of $27.7 million, or 72 percent, from $38.5 million in the comparable period of 2010. This increase primarily reflects higher contract service and personnel-related costs, and includes increased expenses of $26.0 million for product candidates and technology platform development activities that are categorized in the biosciences segment, increased expenses of $1.1 million categorized in the biodefense segment, and increased expenses of $0.7 million in other research and development.
Selling, General and Administrative
For 2Q 2011, selling, general and administrative expenses were $20.4 million, an increase of $2.7 million, or 15 percent, from $17.6 million in 2Q 2010. This increase is primarily due to approximately $2.2 million in restructuring charges related to our UK operations.
For the six month period of 2011, general and administrative expenses were $38.6 million, an increase of $4.8 million, or 14 percent, from $33.8 million in the comparable period of 2010. This increase is primarily due the UK restructuring charges and increased personnel and professional services to support growth of the business.
Financial Condition and Liquidity
Cash and cash equivalents combined with investments at June 30, 2011 was $127.1 million compared to $171.0 million at December 31, 2010. Additionally, at June 30, 2011, the accounts receivable balance was $47.3 million, which is comprised primarily of unpaid amounts due related to shipments of BioThrax received and accepted by the US government in the second quarter of 2011.
2011 Forecast
For the full year 2011, the Company is revising its financial forecast of total revenues and net income. The Company anticipates total revenues of $270 to $290 million and net income of $15 to $25 million. The reduction of 2011 expected total revenue is primarily driven by lower than expected fermentation yields during the six month period of 2011, which, in turn, is expected to result in an annual output this year of approximately 7 million doses.
For the third quarter of 2011, the Company anticipates total revenues of $50 to $60 million.
Conference Call and Webcast
Company management will host a conference call at 5:00 pm Eastern on August 4, 2011 to discuss the financial results for the second quarter and first six months of 2011, recent business developments, revenue guidance for the third quarter of 2011 and revenue and net income guidance for full year 2011. The conference call will be accessible by dialing 888/713-4214 or 617/213-4866 (international) and providing passcode 23117164. A webcast of the conference call will be accessible from the company’s website at www.emergentbiosolutions.com, under “Investors”.
A replay of the conference call will be accessible, approximately two hours following the conclusion of the call, by dialing 888/286-8010 or 617/801-6888 and using passcode 93267041. The replay will be available through August 18, 2011. The webcast will be archived on the company’s website, www.emergentbiosolutions.com, under “Investors”.
About Emergent BioSolutions Inc.
Emergent BioSolutions protects and enhances life by developing and manufacturing vaccines and therapeutics that are supplied to healthcare providers and purchasers for use in preventing and treating disease. Emergent’s marketed and investigational products target infectious diseases, oncology and autoimmune disorders. Additional information about the company may be found at www.emergentbiosolutions.com.
Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including any potential future securities offering, our expected revenue and net earnings for 2011, and any other statements containing the words "believes", "expects", "anticipates", "plans", "estimates" and similar expressions, are forward-looking statements. Such statements are based upon the current beliefs and expectations of management that are subject to risks, uncertainties and other important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax® procurement; our ability to obtain new BioThrax® sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax®; our ability to perform under our current development contracts with the U.S. government; our plans to expand our manufacturing facilities and capabilities, including our ability to develop and obtain regulatory approval for large-scale manufacturing of BioThrax® in our large-scale vaccine manufacturing facility in Lansing, Michigan; the rate and degree of market acceptance of our products and product candidates; the success of preclinical studies and clinical trials of our product candidates and post-approval clinical utility of our products; the potential benefits of our existing collaborations and our ability to selectively enter into additional collaborative arrangements; the extent to which our licensing and acquisition activities are complementary to the company or whether anticipated synergies and benefits are realized within expected time periods; our ability to identify and acquire or in-license products and product candidates that satisfy our selection criteria; ongoing and planned development programs, preclinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2011 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
Financial Statements Follow
| Emergent BioSolutions Inc. and Subsidiaries | |||||
|---|---|---|---|---|---|
| Consolidated Balance Sheets | |||||
| (in thousands, except share and per share data) | |||||
| December 31, | |||||
| 2010 | |||||
| ASSETS | |||||
| Current assets: | |||||
| Cash and cash equivalents | 122,094 | $ | 169,019 | ||
| Investments | 5,048 | 2,029 | |||
| Accounts receivable | 47,263 | 39,326 | |||
| Inventories | 17,262 | 12,722 | |||
| Deferred tax assets, net | 7,082 | 2,638 | |||
| Income tax receivable, net | 17,136 | 8,728 | |||
| Restricted cash | 217 | 217 | |||
| Prepaid expenses and other current assets | 7,742 | 8,814 | |||
| Total current assets | 223,844 | 243,493 | |||
| Property, plant and equipment, net | 172,481 | 152,701 | |||
| In-process research and development | 51,400 | 51,400 | |||
| Goodwill | 5,029 | 5,029 | |||
| Assets held for sale | 12,548 | 12,741 | |||
| Deferred tax assets, net | 27,970 | 33,757 | |||
| Other assets | 712 | 1,198 | |||
| Total assets | 493,984 | $ | 500,319 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
| Current liabilities: | |||||
| Accounts payable | 32,182 | $ | 25,409 | ||
| Accrued expenses and other current liabilities | 1,200 | 1,309 | |||
| Accrued compensation | 13,823 | 23,975 | |||
| Contingent value rights, current portion | 9,734 | - | |||
| Long-term indebtedness, current portion | 10,229 | 17,187 | |||
| Deferred revenue, current portion | 5,336 | 7,839 | |||
| Total current liabilities | 72,504 | 75,719 | |||
| Long-term indebtedness, net of current portion | 29,074 | 30,239 | |||
| Deferred revenue, net of current portion | 2,953 | 4,386 | |||
| Contingent value rights, net of current portion | 6,206 | 14,532 | |||
| Other liabilities | 2,017 | 1,882 | |||
| Total liabilities | 112,754 | 126,758 | |||
| Commitments and contingencies | - | - | |||
| Stockholders’ equity: | |||||
| Preferred stock, 0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively | - | - | |||
| Common stock, 0.001 par value; 100,000,000 shares authorized, 35,850,658 and 35,011,423 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively | 36 | 35 | |||
| Additional paid-in capital | 213,320 | 197,689 | |||
| Accumulated other comprehensive loss | (2,771 | ) | (2,110 | ) | |
| Retained earnings | 166,663 | 173,850 | |||
| Total Emergent BioSolutions Inc. stockholders' equity | 377,248 | 369,464 | |||
| Noncontrolling interest in subsidiary | 3,982 | 4,097 | |||
| Total stockholders’ equity | 381,230 | 373,561 | |||
| Total liabilities and stockholders’ equity | 493,984 | $ | 500,319 |
All values are in US Dollars.
| Emergent BioSolutions Inc. and Subsidiaries | ||||||
|---|---|---|---|---|---|---|
| Consolidated Statements of Operations | ||||||
| (in thousands, except share and per share data) | ||||||
| Three Months Ended | ||||||
| June 30, | ||||||
| 2011 | 2010 | |||||
| (Unaudited) | ||||||
| Revenues: | ||||||
| Product sales | $ | 71,479 | $ | 55,872 | ||
| Contracts and grants | 16,662 | 6,266 | ||||
| Total revenues | 88,141 | 62,138 | ||||
| Operating expenses: | ||||||
| Cost of product sales | 16,069 | 11,076 | ||||
| Research and development | 31,481 | 18,602 | ||||
| Selling, general and administrative | 20,384 | 17,649 | ||||
| Income from operations | 20,207 | 14,811 | ||||
| Other income (expense): | ||||||
| Interest income | 24 | 376 | ||||
| Interest expense | (6 | ) | (2 | ) | ||
| Other income (expense), net | (39 | ) | 6 | |||
| Total other income (expense) | (21 | ) | 380 | |||
| Income before provision for income taxes | 20,186 | 15,191 | ||||
| Provision for income taxes | 7,663 | 5,757 | ||||
| Net income | 12,523 | 9,434 | ||||
| Net loss attributable to noncontrolling interest | 1,687 | 374 | ||||
| Net income attributable to Emergent BioSolutions Inc. | $ | 14,210 | $ | 9,808 | ||
| Earnings per share - basic | $ | 0.40 | $ | 0.32 | ||
| Earnings per share - diluted | $ | 0.39 | $ | 0.31 | ||
| Weighted-average number of shares - basic | 35,619,514 | 31,097,445 | ||||
| Weighted-average number of shares - diluted | 36,667,452 | 31,900,000 |
| Emergent BioSolutions Inc. and Subsidiaries | |||||||
|---|---|---|---|---|---|---|---|
| Consolidated Statements of Operations | |||||||
| (in thousands, except share and per share data) | |||||||
| Six Months Ended | |||||||
| June 30, | |||||||
| 2011 | 2010 | ||||||
| (Unaudited) | |||||||
| Revenues: | |||||||
| Product sales | $ | 77,076 | $ | 94,725 | |||
| Contracts and grants | 29,598 | 14,213 | |||||
| Total revenues | 106,674 | 108,938 | |||||
| Operating expenses: | |||||||
| Cost of product sales | 17,137 | 18,584 | |||||
| Research and development | 66,240 | 38,524 | |||||
| Selling, general and administrative | 38,596 | 33,841 | |||||
| Income (loss) from operations | (15,299 | ) | 17,989 | ||||
| Other income (expense): | |||||||
| Interest income | 59 | 764 | |||||
| Interest expense | (6 | ) | (7 | ) | |||
| Other income (expense), net | (40 | ) | (2 | ) | |||
| Total other income (expense) | 13 | 755 | |||||
| Income (loss) before provision for (benefit from) income taxes | (15,286 | ) | 18,744 | ||||
| Provision for (benefit from) income taxes | (4,636 | ) | 7,392 | ||||
| Net income (loss) | (10,650 | ) | 11,352 | ||||
| Net loss attributable to noncontrolling interest | 3,463 | 979 | |||||
| Net income (loss) attributable to Emergent BioSolutions Inc. | $ | (7,187 | ) | $ | 12,331 | ||
| Earnings per share - basic | $ | (0.20 | ) | $ | 0.40 | ||
| Earnings per share - diluted | $ | (0.20 | ) | $ | 0.39 | ||
| Weighted-average number of shares - basic | 35,400,906 | 30,989,308 | |||||
| Weighted-average number of shares - diluted | 35,400,906 | 31,666,976 |
| Emergent BioSolutions Inc. and Subsidiaries | ||||||
|---|---|---|---|---|---|---|
| Consolidated Statements of Cash Flows | ||||||
| (in thousands) | ||||||
| Six Months Ended | ||||||
| June 30, | ||||||
| 2011 | 2010 | |||||
| (Unaudited) | ||||||
| Cash flows from operating activities: | ||||||
| Net income (loss) | $ | (10,650 | ) | $ | 11,352 | |
| Adjustments to reconcile to net cash provided by (used in) operating activities: | ||||||
| Stock-based compensation expense | 5,150 | 3,363 | ||||
| Depreciation and amortization | 4,514 | 2,646 | ||||
| Deferred income taxes | 3,129 | 3,437 | ||||
| Non-cash development expenses from variable interest entities | 3,348 | 185 | ||||
| Impairment of long-lived assets | 193 | 1,029 | ||||
| Change in fair value of contingent value rights | 1,408 | - | ||||
| Excess tax benefits from stock-based compensation | (1,786 | ) | (709 | ) | ||
| Other | 43 | (29 | ) | |||
| Changes in operating assets and liabilities: | ||||||
| Accounts receivable | (7,937 | ) | 9,107 | |||
| Inventories | (4,540 | ) | (3,595 | ) | ||
| Income taxes | (8,408 | ) | (6,214 | ) | ||
| Prepaid expenses and other assets | 1,557 | 159 | ||||
| Accounts payable | (766 | ) | 4,151 | |||
| Accrued expenses and other liabilities | 26 | (329 | ) | |||
| Accrued compensation | (10,152 | ) | (3,346 | ) | ||
| Deferred revenue | (3,936 | ) | (14 | ) | ||
| Net cash (used in) provided by operating activities | (28,807 | ) | 21,193 | |||
| Cash flows from investing activities: | ||||||
| Purchases of property, plant and equipment | (16,795 | ) | (8,631 | ) | ||
| Proceeds from maturity of investments | 2,250 | - | ||||
| Purchase of investments | (5,269 | ) | - | |||
| Net cash used in investing activities | (19,814 | ) | (8,631 | ) | ||
| Cash flows from financing activities: | ||||||
| Proceeds from borrowings on line of credit | - | 15,000 | ||||
| Issuance of common stock subject to exercise of stock options | 8,695 | 2,784 | ||||
| Principal payments on long-term indebtedness and line of credit | (8,123 | ) | (31,621 | ) | ||
| Excess tax benefits from stock-based compensation | 1,786 | 709 | ||||
| Net cash provided by (used in) financing activities | 2,358 | (13,128 | ) | |||
| Effect of exchange rate changes on cash and cash equivalents | (662 | ) | (165 | ) | ||
| Net increase (decrease) in cash and cash equivalents | (46,925 | ) | (731 | ) | ||
| Cash and cash equivalents at beginning of period | 169,019 | 102,924 | ||||
| Cash and cash equivalents at end of period | $ | 122,094 | $ | 102,193 |